about
A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT.Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation.Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation.Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation.Evaluation of the factor V HR2 haplotype as a risk factor for ischemic cerebrovascular disease.
P50
Q35218515-CAD2E98F-DBE3-4317-B21E-E9732B425F37Q35231363-C0ECC988-1664-40C4-A0BA-24B682494C57Q35231368-30DBA328-E7FE-4850-BDC7-BBAEAE99484AQ36674480-770991CE-F4A5-4C63-81BB-33BC1E954AFDQ38378907-57A62437-16F0-4EB0-8969-47611870FDB3Q40508324-05C312CA-5B6E-4E34-AF5C-FD477AEE0BE9Q48380228-A757DDC0-9F9D-40A6-B1D0-940BF35B24AE
P50
description
researcher
@en
wetenschapper
@nl
name
Izaskun Ceberio
@en
Izaskun Ceberio
@nl
type
label
Izaskun Ceberio
@en
Izaskun Ceberio
@nl
prefLabel
Izaskun Ceberio
@en
Izaskun Ceberio
@nl
P106
P31
P496
0000-0001-8760-2714